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Edited by Michael R. BubbAbstract Expression of the MHC class I allelle, HLA-B27, is
correlated with autoimmune disease. The misfolding and asso-
ciation of B27 heavy chains through non-native disulﬁde bonds
has recently been implicated. Here, we propose that b2m-free,
peptide-free heavy chains support a helix-coil transition in the
segment leading from the a2 domain to the a3 domain,
facilitating rotation of backbone angles around residues 167/
168, and allowing residues 169–181 (identical to a known B27
ligand) to loop around and occupy the molecule’s own peptide-
binding cleft. Such ‘auto-display’, occurring either within B27
molecules, or between B27 molecules, could provoke autoimmune
attack.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The autoimmune disease, ankylosing spondylytis (AS), is
known to have a greater than 90% correspondence with the
expression of HLA-B27, a Class I MHC protein [1]. The mo-
lecular mechanisms responsible for this correspondence are not
yet understood. Previous hypotheses have focused on several
possibilities, which are summarized below:
(A) Antigenic (arthritogenic) peptide display by B27. Investiga-
tors have explored the possible presentation of bacterial
antigens, or bacterial antigen-like self peptides (including
B27-derived peptides) by either B27 itself, or by other
MHC Class I chains, or MHC Class II chains [2–8]. How-
ever, no mechanism explaining this disease has emerged.
(B) Structural organization of b2-microglobulin (b2m)-free
B27. Unlike other MHC Class I chains that only become
competent for peptide-binding in their b2m-bound forms,
B27 chains in the b2m-free form have been observed to (i)
bind peptides [9] and (ii) display a tendency to associate
into large aggregates as well as homodimers stabilized
structurally by disulﬁde-bonds formed between chains* Corresponding author. Fax: +91-172-2744401.
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doi:10.1016/j.febslet.2004.08.037[10,11]. Since the rates and eﬃciencies of association of
b2m with diﬀerent MHC Class I chains vary widely [12],
and it is also known that b2m tends to be shed by cell sur-
face MHC complexes [13], it is considered possible that
B27 chains lacking bound b2m appear on the cell surface
in a peptide-displaying, structure-retaining form that may
be somehow linked to disease; however, the actual exper-
imental evidence currently available to show that b2m-free
B27 binds peptides [9] still needs to be treated with some
caution, at least until there is a larger body of evidence
to support it. Some models involving disulﬁde bonding
of Cys67 have been advanced [11], whereas a recent pro-
posal also suggests the involvement of both Cys67 and
Cys164 [14], in addition to a link between homodimer for-
mation and the kinetics of assembly of HLA chains with
the b2m subunit. Despite the obvious novelty and elegance
of some of these proposals, the exact nature of the b2m-
free form (or forms) that might stimulate autoimmunity
still remains to be established, leaving open scope for fur-
ther discussions and hypotheses.
(C) Amyloid formation by surface-shed b2m. The possibility
has been raised that release of b2m chains by cell-surface
B27 results in the deposition of b2m in synovial ﬂuids in
the form of amyloid aggregates, inviting immune re-
sponses against such aggregates [15]. In this particular
scheme, of course, B27 itself remains incidental (rather
than central) to the disease mechanism.
(D) Production of anti-B27 antibodies. Antibodies against
B27 chains that also show some cross-reactivity with
other MHC Class I chains have been detected in diseased
patients [6,16]. Because B27 is a ‘self’ protein, immuno-
logical dogma would normally suggest that in the ab-
sence of associated defects in immune system
development and/or functioning, no antibodies to such
a protein should be produced. Thus, the presence of an-
tibodies indicates possible additional involvement of the
T-cell-independent B-cell arm of the immune system in
the etiology of disease. The exact mechanisms, if any, re-
main to be deciphered.
In this paper, a novel molecular rationalization is proposed
which reconciles three out of the four possibilities (A, B and
D) above into a single mechanistic explanation for how a
particular misfolded form of B27 could invite autoimmune
attack.blished by Elsevier B.V. All rights reserved.
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2.1. Conformational and associational equilibria of b2m-free
and b2m-bound forms
Fig. 1(a) shows a regular ribbon-diagram representation of
the B27 chain in its b2m-bound, peptide-bound form. In the
previous section, we have already reviewed evidence that b2m-
free B27 is capable of binding to, and displaying, peptides.
Therefore, a schematic representing such a peptide-bound, but
b2m-free form of B27 is shown in Fig. 1(b), essentially to
emphasize that this form could be in dynamic equilibrium with
the form shown in Fig. 1(a). Notably, in this form, whereas the
structure of the ﬁrst two domains of B27 (a1 and a2) is thought
to be native-like, the third domain (a3) may be conceived to be
swinging around in the solvent because there is no b2m present
to bind and stabilize the domain in relation to the main part of
the molecule that operates to bind to the peptide ligand. A
third form that could potentially be in equilibrium with these
two forms would be a peptide-free, as well as b2m-free, form of
B27 as shown in Fig. 1(c). The implicit assumption for this
form to exist detectably, of course, would be that b2m-free B27
would have a suﬃciently lowered aﬃnity for peptide to allow
peptides to dissociate and reassociate with the pocket of the
b2m-free B27. A fourth conceivable population participating
in the equilibrium is a b2m-free form that is also not bound by
a peptide ligand but which is conformationally altered, how-
ever, in a manner that allows a section of its own chain
(identical in sequence to a known B27 ligand) to occupy its
peptide-binding cleft through an act of autodisplay (as dis-Fig. 1. Proposed equilibria amongst various associational and confor-
mational states of HLA-B27. Details are marked on the ﬁgures, and
described in the main text. In panels a and b, the schematic purports to
show the peptide, N-RRYLENGKETLQR-C, bound to the peptide-
binding cleft (in actual fact, the ﬁgure is based on coordinates for an-
other bound peptide, N-GRFAAAIAK-C). In panel b, the bound
peptide is still shown; however, without the associated b2m subunit. In
panel c, the cleft is empty; however, the region of the B27 chain con-
taining the sequence RRYLENGKETLQR (comprising residues 169–
181, identical to a known B27 ligand peptide) is shown in dark black.
This region consists partly of a helix and partly of an interdomain chain
segment of irregular structure that leads from domains a1/a2 (the
peptide-binding section) into domain a3. In panel d, this region is shown
to have undergone a helix-coil transition, and looped around to bind to
the peptide-binding cleft lying next to it (accompanied by movement of
a3 with respect to a 1/a2) in the same binding conﬁguration adopted by
the separately bound peptide shown in panels a and b.cussed later) facilitated by the absence of b2m. This fourth
form is represented in Fig. 1(d).
The view of the peptide-binding section of the B27 molecule
(comprising its a1 and a2 domains) presented in Fig. 1(a)–(d)
is the same; however, since in Fig. 1(d) the geometric rela-
tionship of the a3 domain with the a1 and a2 domains is
changed to allow residues 169–181 to bind, this fact is only
noted upon careful observation. Further, it must be remarked
that these ﬁgures do not attempt to depict possible interactions
amongst b2m-free B27 chains occurring, e.g., through one
chain binding a polypeptide segment of a neighboring chain, as
the complexity of such interactions lies outside the pale of
what may be shown simply with a schematic diagram. We also
wish to draw attention to the fact that none of the ﬁgures in
this paper show the cell membrane; however, it may be as-
sumed that in all cases where the a3 domain is shown, its C-
terminal section is implicitly assumed to be linked to the
roughly 25 residues-long hydrophobic tail of the B27 molecule
that anchors the B27 heavy chain to the membrane.
2.2. The scope for self-display
A sequence of amino acids within the B27 chain (RRY-
LENGKETLQR) spanning residues 169–181 is homologous
to certain bacterial proteins believed to be arthritogenic. From
amongst the residues in this region of the B27 chain, the stretch
comprising residues 168–176 has been shown to bind to the
peptide-binding groove of B27 when it is presented to b2m-
bound B27 as a free peptide [2]; a somewhat longer stretch of
residues, comprising residues 169–179, has been shown to be a
natural ligand of the B2705 and B2702 disease-associated
subtypes of B27, but not of the B2703 subtype that shows poor
association with disease [7,8,17]; an even longer stretch of
residues from this region, comprising residues 169–181, has
been shown to be a natural ligand of the B2705 subtype. Ini-
tially, these discoveries gave rise to the view that peptides
containing residue sequences from this region are generated
through proteolytic processing of B27, leading to their binding
and display to the immune system. However, no clear ratio-
nalization of exactly why this leads to disease has ever
emerged. Below, we oﬀer a viable alternative.
2.3. A structural mechanism for auto-(self)-display
Structurally, residue 169 falls just after a junction separating
two contiguous, almost co-directional helices diﬀering very
slightly in orientation (see Fig. 1(c)). The ﬁrst of these helices
forms a wall of the B27 peptide-binding cleft. As the ﬁgure
shows, the junction of the two helices lies extremely close to the
N-terminus of the peptide occupying the cleft of B27. Now, we
may note that this peptide lying within the cleft of the B27
molecule could very well have been the peptide, N-RRY-
LENGKETLQR-C, that is known to be identical in sequence
to residues 169–181 of the B27 chain itself. Of course, it must
be mentioned that in the crystal structure coordinate ﬁle that
was used to create the schematic shown in Fig. 1(c), the se-
quence of the peptide bound to B27 was actually N-
GRFAAAIAK-C; however, this is an insigniﬁcant detail since,
in any case, the ﬁgure is merely a schematic meant to convey
the idea that the location of the N-terminus of the normally
bound peptide is very close to residues 167 and 168 which
precede a chain segment capable of binding to the B27 cleft.
Residue 169 is located just after the junction, at the beginning
of the second helix leading out of the cleft and directly into a
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join the ﬁrst two domains of the B27 chain, a1 and a2, to the
third domain, a3. It would be obvious from Fig. 1(a) that the
geometric relationship of a3 to the a1 and a2 domains (com-
prising the peptide-binding section of the molecule) is deter-
mined principally by the binding of b2m, since this subunit
binds both to a3 and to the beta sheet ﬂoor of the peptide-
binding section formed by domains a1 and a2. Thus, in the
absence of b2m there are unlikely to be enough stabilizing
contacts to keep the interdomain chain segment structured. As
a consequence, the a3 domain is likely to become mobile with
respect to the peptide-binding section. Therefore, in the b2m-
free form, (i) the loss of structure in the interdomain chain
segment and (ii) the consequent mobility of the a3 domain
could cause destabilization of the immediately preceding helix
containing residues 169–181 since this helix, in any case, makes
very few contacts with other regions of the chain. In the ab-
sence of bound-b2m, therefore, we propose that this helix
simply unravels to adopt a randomly coiled conformation.
Since it contains a part of the amino acid sequence cognate to
the pocket (N-RRYLENGKETLQR-C, comprising residues
169–181) and is also proximal to the cleft, we further propose
that motions of the a3 domain with respect to the peptide-
binding section allow the chain to simply form a short loop
allowing residues 169–181 to bind to the peptide-binding cleft.
Of course, this is accompanied by a change in the geometric
relationships amongst the domains, as suggested by the sche-
matic shown in Fig. 1(d); however, the structures of the indi-
vidual domains are conceived to remain largely native-like,
with the exception of the regions around the peptide-binding
cleft.
Since the a3 domain is anchored to the membrane through a
long hydrophobic tail of about 25 residues, the increased
ﬂexibility (in the absence of b2m) within the interdomain
segment separating the a3 domain from the peptide-binding
section could be conceived to facilitate the following detailed
changes in the geometric relationship amongst domains. Or-
dinarily, the short inter-domain segment emerges from the
helix situated at one end of the peptide-binding cleft (i.e., the
end that is proximal to the N-terminus of any bound peptide).
The segment then descends to connect to the a3 domain sta-
bilized by interactions with b2m. In the absence of b2m, upon
the occurrence of the helix-coil transition, the interdomain
segment of about 5–6 residues becomes essentially made longer
by an additional 7 residues that are added onto its N-terminal
end through the unfolding of the helix beginning at residue 169
(2 turns; 3.4 residues per turn). Therefore, nearly 12–13 resi-
dues are now available in the form of a random coil. As is well
known, the polypeptide backbones of random coils contain
two bonds per residue around which rotation can occur with
ease, since only the peptide bonds in the backbone are rota-
tionally restrained. This rotational freedom of the random coil
allows it to ﬂex itself in various ways with respect to ﬂanking
domain structures. We propose that the lengthening of the
interdomain segment as a result of helix unfolding allows the
segment to now explore and occupy the peptide-binding cleft
so that it can traverse the entire length of the cleft (about 9
residues) before descending to meet the a3 domain, from the
opposite end of the cleft. Of course, with respect to the
membrane-anchored a3 domain, this would probably end up
involving an eﬀective rotation of the peptide-binding section
(including the ﬂoor of the peptide-binding cleft) by about 180degrees, around an axis roughly perpendicular to the mem-
brane. Following this transformation, the peptide-binding cleft
would still face away from the membrane with its ﬂoor posi-
tioned roughly parallel to the membrane. At any rate, even if
this were not exactly so, it might be envisaged that the auto-
displaying cleft would still remain accessible to T-cell recep-
tors, since the only transformation occurring would be that the
interdomain segment would traverse the cleft and descend to
meet the a3 domain from the opposite end of the cleft from the
one from which it ordinarily descends; suﬃcient ﬂexibility
could be expected to remain in the interdomain segment (res-
idues 180–186), and also in the region between the a3 domain
and the membrane spanning domain, to allow TCRs to access
the altered peptide-binding segment.
Classically, MHC Class I chains are known to largely bind
nonameric peptides [18,19]. Here, however, given the confor-
mational changes proposed, it may be envisaged that the
restrictions ordinarily applicable to the ends of the peptide-
binding cleft remain no longer applicable due to the changes
occurring at the ends of the cleft. In the next section of this
paper, we present molecular modeling studies that appear to
support the feasibility of the structural changes envisaged
above.3. Support from molecular modeling studies
The coordinates for the complex of HLA-B27 with a no-
nameric peptide ligand, N-GRFAAAIAK-C, were obtained
from the RCSB database (ﬁle name: 1K5N.pdb). Using Insight
II (2000) software, CVFF force ﬁelds, and a Silicon Graphics
Fuel workstation for modeling, the chains corresponding to
the (a) nonameric peptide ligand and (b) B27-associated b2m
subunit were deliberately removed from the structure coordi-
nate ﬁle, to leave only the atoms and coordinates corre-
sponding to the heavy chain of B27. The backbone dihedral
angles for residues 167 and 168 of the B27 chain were then
rotated to allow residues 169–181 to be roughly juxtaposed
opposite to the (now empty) peptide-binding cleft of B27;
however, this was done without changing any other structural
parameter or altering the short helical region of the chain
following residue 167 and preceding the linker region leading
into the a3 domain. The structures of two stretches of the
chain comprising residues 1–167, and 182–276, were kept re-
strained, so that any structural freedom would be available to
only the stretch between residues 168 and 181. The structure
generated through the changes in dihedral angles was then
minimized through a combination of steepest descent and
conjugate gradient methods, using a convergence criterion of
0.1, to obtain a suitable starting conformation for residues
169–181 for use in molecular dynamics simulations. High
temperature dynamics was performed, using the same con-
formational restraints as before, with 50 cycles of heating to
500 K (at the rate of 50 K per ps) and cooling to 300 K (at the
rate of 30 K per ps), followed by 30 ps of molecular dynamics
simulations at 300 K. Structure minimization for the best 50
structures was then carried out, this time without structural
restraints, with a convergence criterion of 0.01. All MD cal-
culations were performed with a distance-dependent dielectric,
i.e., with implicit solvent rather than with explicit solvent in-
volving water molecules.
Fig. 2. The structure at the top is the structure of the B27 chain, shown
bound to a peptide, N-GRFAAAIAK-C. The peptide is shown in blue.
The combined a1 and a2 domains of the B27 chain are shown in
yellow, while the a3 domain of the same chain is shown in red (behind
a1 and a2). The region of the chain comprising a helix and an un-
structured linker leading into a3 is shown in green. The b2m subunit
implicit to this structure is not shown, to simplify the visual repre-
sentation and to facilitate direct comparison with the remodeled
structure shown in the lower panel. The lower panel shows the mod-
eled structure. This was obtained (a) by changing backbone dihedral
angles of residues 167 and 168 [to turn the green section of the chain
around to juxtapose residues 169–181 opposite to the peptide-binding
cleft and change the geometric relationship of the a1/a2 (yellow) and
a3 (red) domains], and (b) by carrying out a combination of structure
minimization and molecular dynamic simulations. The region shown
in green (including a helical section, and a region of the chain in ir-
regular structure) is seen to have transformed into extended confor-
mation, thus allowing this section of the chain to bind to the molecule’s
own peptide-binding cleft, in the absence of peptide (blue).
Fig. 3. Detailed structure of the B27 chain engaged in auto-display,
derived through molecular dynamics performed for the equivalent of
over 3000 ps of simulations. The upper panel shows the view of the
molecule as one looks down upon the peptide-binding cleft from
above. The lower panel shows the side-view, obtained by turning the
view shown in the upper panel by 90 around a horizontal axis. The
polypeptide is shown superimposed upon a transparent rendition of
the molecule’s surface. The use of transparency along with orthogonal
views facilitates simultaneous assessment of the depth and intimacy of
interactions occurring within the cleft. In both panels, the large mass
on the left represents the combined a1 and a2 domains, while the
smaller mass on the right shows the a3 domain which is anchored
through a C-terminal hydrophobic domain (not shown) to the mem-
brane. The section of residues from W166 to R181 is shown entering
and occupying the peptide-binding cleft in an all-atom (thick bonds)
CPK representation. The remaining molecule is shown in a backbone-
only (thin bonds) CPK representation. R170 occupies pocket D,
Y171 occupies pocket B, K176 occupies pocket C, and E 177 occupies
pocket F.
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structure shown in the bottom panel of Fig. 2, which repre-
sents a real minimized structure that also serves simultaneously
as a good schematic representation of the proposed changes in
the molecule, with color coding of diﬀerent sections (as de-
scribed in the ﬁgure legend). It may be noted from inspection
of this structure that the second helix in the wall of the peptide-
binding cleft (which was proposed to undergo a helix-coil
transition) is no longer a helix. Rather, the helix would appear
to have rearranged, following high temperature dynamics, to
cause the entire region of the chain to adopt an extended
conformation that (following further molecular dynamics and
minimization) happens to optimally position residues 169–181
into the peptide-binding cleft, by forming a loop at the point in
the chain (near 167 and 168) earlier placed at the beginning of
a short helix leading into the a3 domain. It may also be noted
that some crucial residues ordinarily contributing to the for-
mation of pocket A in the peptide-binding cleft (e.g., W167
and Y171) are relocated such that pocket A no longer exists.
These residues are now engaged in supporting the extended
conformation of the residues entering and occupying the cleft.
The fact that this structure survived MD simulations over 30
ps suggests that it is a reasonably stable structure, as well as a
feasible structure. For comparison, the normal structure of the
B27 chain in complex with bound peptide (however, not
showing the b2m) is shown as the top panel of Fig. 2. Com-parison of the clefts in the two structures reveals structural
readjustments in the auto-displaying chain.
We wished to further explore the kinetic stability of this
structure through longer MD simulations, and carry out a
more detailed examination of what would appear to be hap-
pening inside the cleft. Therefore, a further 3000 ps of simu-
lations was performed at 300 K. Initially, this was attempted
with explicit solvent included (i.e., with water molecules inside
a box enclosing all protein atoms), with no conformational
restraints. However, such simulations proceeded extremely
slowly given the available system resources, with dynamics
proceeding at the rate of only a few picoseconds per week.
Therefore, after only about 10 ps of such simulations, we
switched to an implicit solvent mode (with distance-dependent
dielectrics), and with restraints imposed on all residues other
than the stretch within the pocket, to complete several thou-
sand picoseconds of simulations and examine whether the
stretch was still within the cleft. The minimized structure de-
rived from this study is shown in Fig. 3 in the form of two
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bottom view shows the cleft from the side. The peptide posi-
tioned within the groove is depicted through a CPK repre-
sentation that uses thick bonds, showing all atoms embedded
within a surface representation that has deliberately been kept
‘transparent’ to allow simultaneous viewing of both the mol-
ecule’s overall surface and the topology of its chain. For this
purpose, the rest of the B27 molecule is also shown through a
CPK representation; however, this is done through the de-
piction of only backbone atoms, again embedded within a
transparent surface representation of all atoms, this time with
thin bonds used to show the backbone. The two views are
being deliberately shown to allow viewers to see the molecular
surface while at the same time: (a) distinguishing between the
sections of the B27 molecule forming the cleft and the section
bound within the cleft and (b) ascertaining that the peptide is
well ensconced and buried deep within the cleft. The surface
representation indicates an optimized and intimate set of in-
teractions of the cleft with its contents, in the minimized
structure.
Detailed analysis of the conformation of the bound peptide
within the cleft, through calculation of atom–atom distances
between residues forming the cleft and those occupying the cleft
suggests the following. At one end of the cleft, pocket A no
longer exists, as already mentioned. Ordinarily, residue 62 locks
in the N-terminus of any peptide bound in the cleft. However,
with the rearrangement of other residues constituting pocket A,
such as residues 167 and 171, the lock on this end of the cleft is
eﬀectively removed, allowing the polypeptide chain to enter the
cleft. At the other end of the cleft, where the chain emerges to
meet the a3 domain, residue K176 appears to occupy pocket C,
whereas residue E177 appears to occupy pocket F. This is in
consonance with the ninth residue from residue R169 entering
pocket F, as would be expected. Perhaps, owing to the absence
of pocket A whose occupation by the ﬁrst residue of a nona-
meric peptide sets the tone for the entry of the remaining resi-
dues into the various pockets, rotations in the backbone appear
to have caused residue R170 to enter pocket D instead of the
expected occupancy of pocket B by this residue. Residue Y171,
which would have been expected to enter pocket D, instead
enters pocket B, and does so in such an intimatemanner that the
ring of the tyrosine sidechain cannot even be seen in an all-atom
top-view if the surface is not made deliberately transparent as
done for the top panel of Fig. 3. Thus, some non-canonical
interactions are observed as may be expected, even though the
sequence of residues anticipated to enter the cleft can be seen to
have entered and occupied the cleft in an intimate and appar-
ently optimized manner. It may be noted for the record that
identiﬁcation of the various pockets in the remodeled B27 chain
was carried out through analysis of residue conﬁgurations that
ordinarily deﬁne pockets in B27 chains as could be gleaned from
the existing literature, in which lists of residues in a nonamer
sequence that ordinarily enter the various pockets are available
[18], as are lists of residues making up the various pockets
themselves [20].4. Correlate: appearance of b2m-free B27 with disease
There is evidence that the availability of free b2m in serum
increases with autoimmune disease [21,22]. Whether this is acause, or a consequence, of disease is not clear. It remains
conceivable, however, that the increase in free b2m levels sig-
nals an increase in the availability of b2m-free HLA chains on
the cell surface. If the cause behind shedding of b2m is
something that happens in adult life due to some yet unknown
stimulus, it is possible that auto-displaying B27 only comes
into existence in the later years during development of disease
and that, therefore, this form does not exist in the embryo, or
in very young persons expressing the allele. Therefore, it may
be assumed that the immune system does not ordinarily see
this form, or naturally eﬀect clonal deletion of cells during the
period in which discrimination of self from non-self is eﬀected.
Therefore, it is possible that during the critical period of thy-
mic education, b2m-free B27 chains are not presented to the
immune system, such that T-cells bearing receptors cognate to
such chains do not get eliminated in the thymus.5. Auto-displaying B27 should appear ‘foreign’ to T-cells and B-
cells
What are the immunological consequences of B27 ‘‘auto-
display’’? For one thing, it may be held that the structural
alterations involved in auto-display could create new confor-
mational epitopes that would appear ‘foreign’ enough to the
circulating population of na€ıve B-cells, allowing binding of
some B-cells bearing cognate immunoglobulin receptors to
cells presenting auto-displaying B27. Simultaneously, the
structural alterations occurring in-and-around the binding
cleft could lead to the occupied cleft also appearing suﬃciently
‘foreign’ in structural format to the T-cell population, allowing
binding of some T-cells through their T-cell receptors. There-
fore, helper T-cells could cause activation of the na€ıve B-cells
binding to autodisplaying B27, and themselves become acti-
vated in the process. Independently, it has also been recently
reported that B27 is capable of interacting non-canonically
with the CD4 receptor [23], bringing into question one of the
most deeply entrenched dogmas concerning MHC Class I in-
teractions with other immune system components. Binding of
T-cells to autodisplaying B27 in this manner could lead to
direct attack by eﬀector T-cells. A further interesting possi-
bility is that na€ıve B-cells could even be activated through
T-independent mechanisms. As is well known, sugars such as
lipopolysaccharides (LPS) that display many copies of a given
carbohydrate-based B-cell epitope over the length of a long
polymeric sugar structure manage to activate B-cells without
any T-cell involvement, due to the ability of such sugars to
eﬀect a cross-linking of B-cell receptors. In this context, it has
recently been suggested [24] that protein aggregates (especially
if formed amongst proteins displayed on a cell surface) can
also similarly activate B-cells through a T-independent mech-
anism, since protein aggregates would be likely to display
multiple copies of a misfolding-derived conformationally for-
eign epitope to na€ıve B-cells over the length and breadth of a
pseudo-polymer-like substratum provided by the aggregation
process itself, to eﬀect cross-linking of B-cell receptors on the
surface of a na€ıve B-cell. Since, as we have already discussed,
B27 heavy chains can conceivably form large assemblies of
conformationally foreign chains through cross-display occur-
ring amongst neighboring molecules, such assemblies might
elicit activation of B-cells and eventually lead to the produc-
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thereof, might potentially help rationalize both the presence of
antibodies in AS patients and the T-cell mediated immune
attack that is characteristic of such auto-immune disease.6. Discussion and conclusions
We have proposed a detailed mechanism for the misfolding
of the HLA-B27 heavy chain in the absence of b2m and shown
that this mechanism is feasible with evidence from molecular
modeling. Brieﬂy, we have argued that:
1. A helix-coil transition in a key region of the chain (follow-
ing residues 167/168) perfectly disposes this region to loop
around and bind to the empty peptide-binding cleft of the
molecule, in an act of auto-display.
2. What potentially facilitates such a conformational transfor-
mation and binding of a section of the B27 chain by its own
peptide-binding cleft is: (a) the proximity of residue 168 to
the N-terminus of any normally bound peptide ligand, (b)
the fact that the region of the chain immediately following
the helix beginning with residue 168 constitutes an interdo-
main segment separating the a3 domain from the combined
a1 and a2 domains, which may be expected to be ﬂexible
enough in a b2m-free B27 chain to cause unfolding of the
helix and (c) the fact that the proposed helix-coil transition
in the region actually occurs during high temperature mo-
lecular dynamics, and stably survives subsequent dynamics.
3. High-aﬃnity binding of the region following residue 168 to
the B27 peptide-binding cleft is made probable by the fact
that the region contains a sequence of residues (RRY-
LENGKETLQR, between residues 169 and 181) that ex-
actly matches the known sequence of a natural peptide
ligand of B27 (N-RRYLENGKETLQR-C).
4. Such ‘auto-display’ is further made feasible by the fact that
B27 retains peptide-binding capability in the absence of
bound b2m, which is something that has been recently
shown, as well as proposed for disulﬁde-bonded misfolded
forms of B27. Auto-display is also made feasible by the fact
that it is expected to destroy the A pocket of the peptide-
binding cleft, facilitating entry of sections of the polypeptide
chain constituting pocket A (e.g., residues 167 and 171) into
the cleft, and occupation of the cleft by residues 169–177 of
the B27 chain, with residues up until residue 179 having
some peripheral associations with the cleft, and residues
180 and 181 remaining outside the cleft to facilitate rota-
tional optimization of interactions with the a3 domain.
We would like to emphasize that whereas we have suggested
a mechanism for auto-display to occur in a principally uni-
molecular fashion, it could also conceivably occur in bimo-
lecular, or multimolecular fashion, with each molecule binding
to a section of a neighboring molecule’s chain. This would
ensure that B27 could potentially exist in a structured form
within large multimolecular assemblies. We have recently ob-
tained experimental evidence (to be published separately) for
the existence of such structured assemblies using peptide-free,
b2m-free B27 chains.
The modeling studies show that the really important sec-
tion involved in autodisplay is the stretch between residues
169 and 179 (or even 169 and 177), since residues 178 and
179 are only peripherally associated with the cleft, and resi-dues 180 and 181 appear to be outside the cleft and in the
section forming the link to the a3 domain. Therefore, upon
ﬁrst consideration, it might be argued that any molecule of
B27 containing residues 169–177 should be capable of
forming the proposed auto-displaying, or cross-displaying
structure(s). Yet, all B27 subtypes are not associated with
disease. Also, all subtypes do not bind with similar aﬃnities
to residues 169–177, or residues 169–179, when these residues
are presented to b2m-bound B27 as free peptides. Certain
details regarding these aspects of binding behavior were given
in Section 2.2, and further details may be found in a recent
publication [25]. What might be the reasons for such diﬀer-
ences in behavior amongst B27 subtypes if indeed all contain
residues 169–177? We feel that a number of diﬀerent expla-
nations might apply, either singly or in combinations. Firstly,
there could be diﬀerences in the tendencies of the various B27
subtypes to dissociate from b2m, rather than diﬀerences in
their individual abilities to bind (or not bind) residues 169–
181, once the heavy chain becomes b2m-free. Secondly, there
could be diﬀerences in the relative conformational stabilities
of the native-like B27 conformation in the b2m-free form,
which would determine whether only a helix-coil transition
would occur initially, allowing the chain to quickly undergo
auto-display, or whether the whole b2m-free molecule would
spontaneously undergo unfolding as is thought to occur
classically with MHC Class I molecules, leaving no scope for
auto-display. Thirdly, there could be diﬀerences in the relative
ﬂexibilities of the various B27 forms around the region (res-
idues 167/168) in which the chain turns around to occupy the
peptide-binding cleft before descending to the a3 domain.
Such diﬀerences could owe to mutation-linked diﬀerences in
the environments of residues 167/168 in various subtypes.
Fourthly, certain mutation-linked diﬀerences in the environ-
ments oﬀered by the peptide-binding cleft(s) of various B27
forms could themselves modulate the aﬃnities of such clefts
for residues from the 169–169 section of the chain when it is
presented as a part of the whole B27 chain. Therefore, the
presence of residues 169–179 would not automatically entitle
an MHC Class I chain of the B27 variety to undergo auto-
display; other factors as listed above could also play a role in
determining whether auto-display would occur.
Another issue that bears reiteration is the question of whe-
ther the conformationally rearranged B27 would be presented
to TCRs. We have already discussed this in some detail in the
latter half of Section 2.3, and argued that from a purely
physical, or steric, point of view, TCRs would be able to access
autodisplaying B27. Of course, this does not address the
question of whether TCRs capable of recognizing the auto-
displaying B27 molecules would be available in the system. We
have argued that they are likely to be available, since the ap-
pearance of b2m-free B27 heavy chains occurs after the de-
velopmental stage at which most thymic education of T-cells
occurs. However, it is possible that all T-cell clones conceiv-
able may not be available, or that only certain varieties of
TCRs might engage in binding to b2m-free B27. For instance,
for disulﬁde-bonded homodimers of misfolded B27 it has been
suggested that peptides displayed and bound by these forms
may be recognized by c/d chain TCRs rather than by a/b chain
TCRs [26]. The same could apply here. We have no speciﬁc
comments to make regarding this, at this time, other than to
say that T-cell responses of both helper and eﬀector types
could occur.
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assembled through cross-display. Indeed, structural analysis
suggests that it is conceivable for residues such as Cys67 and
Cys164, which are known to be involved in B27 associations
[11,14,27], to be brought together by cross-chain auto-display
involving neighboring molecules. Cys164 is a residue that is
proximal to residues 168/169 in the chain and so it would
automatically be positioned near the region of the cleft adja-
cent to the N-terminus of any ordinarily bound peptide.
Likewise, Cys67 is proximal to Arg62 which locks in the N-
terminus of any ordinarily bound peptide in various MHC
class I molecules [28]. Thus, with some minor structural re-
adjustments, residues 67 and 164 of neighboring chains (car-
rying out cross-chain auto-display, or cross-display, of the
kind proposed here) could easily be conceived to form inter-
chain disulﬁde bonds, in addition to the Cys67–Cys67, and
Cys164–Cys164, disulﬁde bonds already proposed for mis-
folded homodimers. It may be remarked here that it is mainly
Cys67 that has been implicated in homodimer formation
through disulﬁde bonding at the cell surface [14]. The in-
volvement of Cys164 has so far been implicated only for ho-
modimers formed in the ER that, interestingly, are thought to
retain much of the native conformation of the heavy chain [27].
Interestingly, one form of homodimer formed in the ER
(which reacts with the W6/32 mAb antibody) has been stated
to be likely to reach the cell surface from the ER [11], sug-
gesting that the cell surface might indeed end up displaying
homodimers formed through disulﬁde bonds involving Cys67
as well as Cys164. The form(s) involving Cys67 disulﬁde
bonding would be anticipated to result from in situ misfolding
of B27 on the cell surface following shedding of b2m. The
form(s) involving Cys164, on the other hand, would be antic-
ipated to result from transport of misfolded B27 from the ER
to the cell surface. Our interest is in pointing out how cross-
display of residues 169–181 between neighboring molecules
appears to be compatible with the formation of disulﬁde bonds
involving Cys67 and/or Cys164. It is possible that the inter-
chain disulﬁdes observed to form in b2m-free B27 chains ac-
tually form because B27 chains bind and display each other’s
polypeptide segments within their peptide-binding clefts, and
that this happens sometimes in an interaction involving only
two molecules (shutting oﬀ further scope for extended cross-
display) and sometimes in interactions involving many more
molecules, because once the process starts with one molecule
binding the next molecule’s chain and the next molecule
binding the chain of the molecule lying next to it, and so on,
the process may not end until steric reasons owing to physical
curving of such assemblies force the assembly to stop. This
reconciles our proposal with hypothesis B mentioned in the
introduction, since experimental evidence for that hypothesis,
in fact, indicates that misfolded B27 chains can form either
homodimers, or large assemblies of chains, but no other spe-
cies of intermediate size. In addition, our proposal also rec-
onciles hypotheses A and D with hypothesis B, because (i) we
invoke and use the concept of the arthritogenic self peptide
(except that we propose that the relevant residue sequence that
is bound and displayed is actually a part of the intact B27
chain), and (ii) we propose the formation of a profoundly
conformationally altered B27 that is argued to be likely to
stimulate all arms of the immune system, including the B-cell
system that could produce antibodies against a foreign (mis-
folded) conformation of a naturally occuring (self) protein.We suggest that the following types of experiments could be
done to test the hypothesis and are currently engaged in car-
rying out some of these experiments. Firstly, speciﬁc mutations
could be made that would allow B27 to fold and bind other
peptides in the classical fashion, but lose the ability to bind to
peptides equivalent to residues 169–181 (or a shorter form, like
169–179) due to alterations in pocket environments within
clefts. Such forms could be tested for their ability to adopt
structured, misfolded assemblies vis a vis their tendency to
unfold in the absence of b2m like ordinary class I MHCs, to
examine which mode of behavior would be adopted. Secondly,
limited mutations in the 169–179 region could be made to
convert the B27 MHCs into other MHCs of the B variety,
followed up with monitoring of conformational behavior in
the absence of b2m. Thirdly, chemical cross-linking experi-
ments combined with proteolysis carried out with a protease of
known speciﬁcity could be done to examine whether any
masses corresponding to cross-links likely to be formed by
auto-display are observed. Fourthly, dissociation parameters
(energies, etc.) of soluble assemblies of b2m-free B27 could be
determined under mildly destabilizing conditions, together
with monitoring of conformational changes, to examine whe-
ther the observed behavior is compatible with the dissociation
of residues from peptide-binding clefts. Finally, protein as-
semblies could be proteolyzed with, or without, reduction of
disulﬁde bonds, to see whether the resulting forms could be
crystallized and studied to reveal hints of any auto- or cross-
display.
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